



Delta-Like Ligand 3 (DLL3) is a promising target in small cell lung cancer

Tarlatamab - Bi-specific T cell engager (BiTE®) (NCT03392064)




Tarlatamab Induces Response in Previously Treated SCLC




Borghaei H, WCLC 2022




DLL3 is highly expressed in neuroendocrine subtypes of SCLC





DLL3 gene expression in SCLC patient samples



DLL3 surface expression in SCLC by subtypes



DLL3-targeting CAR T showed robust in-vitro cytotoxicity against SCLC



DLL3 CAR T in vitro activity (E:T 1:1)

